01 feb: Insideres handel
01 feb: Vilkår for Nykredits og Totalkredits auktioner
01-02-2018 12:02:23

Coloplast delivers solid Q1 interim results and continues to take market share

Relateret indhold
14 maj - 
Aktier/åbning: Positiv stemning fra start med Novo og D..
14 maj - 
Aktier/tendens: Analytikerændringer kan sætte retningen..
14 maj - 
Coloplast/Berenberg: Anbefaling op til "hold" fra "sælg..
Relateret debat
17 maj - 
  Ingen tvivl om COLO er et fantastisk selskab, me..
17 maj - 
Oplagt shortkandidat, hvis man gør sig i shortin..
17 maj - 
Coloplast har været en laaaaaaaaaaaaang limbo (re..

Coloplast delivered 8% organic revenue growth and an EBIT margin of 31% at constant exchange rates in the first quarter of the 2017/18 financial year. The results were in line with the company’s guidance.

Coloplast delivered 8% organic revenue growth in the first three months of the 2017/18 financial year, while reported growth in Danish kroner was up by 5% to DKK 3,955m. Reported revenue was adversely affected by the depreciation of USD and dollar-related currencies against DKK.

EBIT amounted to DKK 1,207m for a 2% decline in DKK but a 4% increase at constant exchange rates. The EBIT margin at constant exchange rates was 31% against 33% in the same period last year. In DKK, the EBIT margin was 31%, against 33% last year.

Organic growth rates by business area: Ostomy Care 9%, Continence Care 10%, Urology Care 11%, and Wound & Skin Care negative at 5%. Organic growth, particularly in the wound care business, was adversely affected by price reforms in Greece.

Looking at sales by geographies, the European markets contributed with 4% growth, Other developed markets delivered 18% revenue growth, while Emerging Markets provided a 10% increase.

  • “We’re delivering a solid result for the first quarter, and we are off to a good start to the financial year. We’re performing well in many of our major markets and are generally delivering strong results in Ostomy Care, Continence Care and Urology Care. As an example, we’re delivering double-digit growth, and we see continued increased momentum in the US market,” says Coloplast CEO Lars Rasmussen. 

Coloplast invests in growth

Coloplast invested in sales and marketing initiatives across multiple markets and business areas during the first quarter as part of its ambition to drive organic growth.

In addition, Coloplast is adding a new product to its ostomy care portfolio with the launch of SenSura® Mio Concave, the first ostomy care product designed specifically for people with hernias or curves. 

  • “We’re proud to be able to offer our users the best products in the market, and I’m confident that this new product will make a big difference to our users while giving Coloplast a strong competitive edge. Our ambition is to continue to win market share, and to do that we need innovative products like SenSura® Mio Concave,” says Mr Rasmussen.

In November 2017, Coloplast presented its new long-term financial guidance for the period to 2020. Consistent with its ambition of pursuing non-organic growth opportunities, Coloplast completed the acquisition of French direct-to-consumer home delivery company SAS Lilial in January 2018.

The transaction will strengthen Coloplast’s position and its product and service offering in France and will open for further access to payers.

Financial guidance for 2017/18

Coloplast continues to expect organic revenue growth of ~7% at constant exchange rates. Guidance for reported growth in DKK is lowered by 1pp to 5%–6% due to developments in the USD/DKK exchange rate. The guidance includes a negative effect of DKK 100m due to the patent expiry of SpeediCath® standard catheters and the effects of a comprehensive healthcare reform in Greece of DKK 100m.

Coloplast continues to expect an EBIT margin of 31%-32% at constant exchange rates and a reported EBIT margin of ~31% in DKK.

CONTACTS

Lina Danstrup

Senior Media Relations Manager, Corporate Communications

+45 49 11 26 07

dklina@coloplast.com

 

Ellen Bjurgert

Director, Investor Relations

+45 49 11 33 76

dkebj@coloplast.com

http://prlibrary-eu.nasdaq.com/Resource/Download/a1aa3833-9a58-4b92-9818-83c0b8055408

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Aktier/tendens: Positiv stemning ser ud til at løfte danske aktier

25-05-2018 08:10:11
Der er lagt op til en positiv dag, når det danske aktiemarked sætter gang i handlen fredag morgen, hvor Ørsted og Pandora kan komme i fokus efter torsdagens store fald.De amerikanske aktier sluttede torsdagen med små minusser, mens de asiatiske aktieindeks lå med blandede fortegn fredag morgen. De amerikanske futures og den tyske DAX-future ligger til gengæld med stigninger omkring en time før den..

Hartmann Q1: Sætter gang i effektiviseringsprogram for at nå 2018-mål

24-05-2018 14:29:06
Fremgang i emballagesalget og et højere teknologisalg prægede årets første kvartal hos emballageproducenten Brødrene Hartmann, der kom ud af perioden med en stigning i både omsætningen og indtjeningen.I første kvartal omsatte virksomheden for 624 mio. kr. mod 572 mio. kr. i samme periode af 2017, og fremgangen kom, på trods af at valutakurser påvirkede omsætningen i år med 55 mio. kr. Det fremgår ..

Pandora/Carnegie: Ser nedjustering komme senere på året

24-05-2018 09:59:22
Smykkekoncernen Pandora har kurs mod en nedjustering senere på året, vurderer Carnegie, som skærer gevaldigt i kursmålet for aktie til 400 kr. fra før 700 kr. og sænker anbefalingen til "sælg" fra "hold". Finanshusets Pandora-analytiker, Lars Topholm, peger også på, at det kan blive nødvendigt at få nye kræfter ind til at få gennemført de nødvendige ændringer i selskabet og genskabe tilliden. Regn..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Norwegian suser til vejrs efter historie om Ryanair-interesse
2
Pandora-analytikere ser fortsat Kina-potentiale trods kursbank - citat
3
Aktier/tendens: Positiv stemning ser ud til at løfte danske aktier
4
Torsdagens aktier: Pandora og Ørsted trak C25 i rødt
5
Aktier/middag: Pandora og Ørsted trækker C25 i rødt

Relaterede aktiekurser

Coloplast B A/S 615,00 1,0% Stigning i aktiekurs
Coloplast 96,90 0,5% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. maj 2018 11:01:59
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180524.2 - EUROWEB5 - 2018-05-25 11:01:59 - 2018-05-25 11:01:59 - 1 - Website: OKAY